18.07.2011
MagForce Nanotechnologies AG Announces Establishment of NanoTherm® Therapy Treatment Center at Charité University Medical Center
Berlin, July 8, 2011 - MagForce Nanotechnologies AG (FSE:MF6), a leading medical technology company focusing on nano medicine in oncology, announced today that the Charité-Universitätsmedizin Berlin published the establishment of its NanoTherm® therapy center for the treatment of recurrent brain tumors on: www.charite.de
“I am pleased that we have accomplished this first step in making NanoTherm® therapy available to brain tumor patients,” said Dr. Peter Heinrich, CEO of MagForce. “There have been many challenges associated with introducing a completely new therapeutic approach to the medical community; therefore, the initial rollout has taken longer than expected. Our sales team is active throughout Germany and currently in discussion with leading medical institutions to establish additional treatment centers. We are also working to make the therapy internationally available.”
Dr. Andreas Jordan, CSO and founder of MagForce added, “We are pursuing the further development of NanoTherm® therapy for the treatment of prostate and pancreatic carcinomas. NanoTherm® therapy has enormous therapeutic potential to treat a variety of solid tumors, and we are just at the beginning.”
ABOUT MAGFORCE NANOTECHNOLOGIES:
MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.
DISCLAIMER:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.